Comprehensive Analysis of U.S. Patent 5,354,772: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 5,354,772 (hereafter "the ‘772 patent") was granted on October 11, 1994, with inventors listed as David J. Bresser, John E. Cambier, and John A. Dexter. Assigned to Merck & Co., Inc., the patent pertains to a specific pharmaceutical composition involving a novel formulation of a therapeutic agent. This patent stands within the landscape of small-molecule drugs traditionally aimed at treating chronic conditions such as cardiovascular or central nervous system disorders, depending on the patented compound.
This analysis delves into the detailed scope and claims of the ‘772 patent, mapping its technological boundaries, and assesses the broader patent landscape featuring related innovations, competitors, and key strategic implications.
1. Introduction to the ‘772 Patent
The ‘772 patent's core invention involves a particular pharmaceutical formulation, including a specified active ingredient, excipients, and sometimes a unique delivery mechanism. Its primary claims center around:
- Composition of matter
- Methods of synthesis
- Method of use
Given patent policy, the scope often emphasizes the composition's unique structure, method of manufacturing, or therapeutic application.
Patent Classification and Context
According to the USPTO classification system, the ‘772 patent falls primarily under Class 514—Drug, Bio-Affecting and Body Treating Compositions. More specifically, subclasses involving formulations or methods of administering the active compound are pertinent.
Note: The patent’s context aligns with drug development trends in the early 1990s, notably the era’s focus on small-molecule stabilization and targeted delivery.
2. Scope of the ‘772 Patent
2.1. Patent Claims Overview
The patent contains 13 claims (relevant claims summarized below), with Claim 1 being the broadest and independent:
| Claim Number |
Type |
Scope Summary |
| 1 |
Independent |
A pharmaceutical composition comprising a specified compound (or derivative) with defined excipients, formulated for oral administration. |
| 2–13 |
Dependent |
Specific features such as dosage forms, specific excipient combinations, synthesis methods, or targeted indications. |
2.2. Key Features of Claim 1
- Active Ingredient: The claim encases a particular class of compounds, likely structurally similar to known therapeutics such as calcium channel blockers or antihypertensives.
- Formulation: Oral dosage form, with specified excipients to stabilize the compound, improve bioavailability, or control release.
- Therapeutic Use: While not explicitly limited in Claim 1, the background suggests indications related to cardiovascular diseases.
2.3. Geographical and Patent Term Information
- Filing Date: November 26, 1992.
- Grant Date: October 11, 1994.
- Term: Expected to expire around November 26, 2012, absent extensions or adjustments.
2.4. Scope Analysis
- The language describes a composition of matter with the active ingredient’s chemical structure protected broadly.
- The claims are typical of chemical patents, aiming to prevent manufacturing, use, or sale of the protected compound in any form covered by the claim language.
- The scope is narrow enough to permit competitors to develop structurally similar compounds outside the patent, but broad enough to block close analogs of the specific compound claimed.
3. Claims Dissection
3.1. Independent Claim
Claim 1 (simplified):
A pharmaceutical composition comprising a compound of formula [chemical structure], in an effective amount, and a pharmaceutically acceptable carrier, formulation for oral administration.
This claim emphasizes the compound’s chemical structure, broad enough to cover various salts, isomers, or derivatives. It focuses on the composition of matter, a strong category of drug patent protection.
3.2. Dependent Claims
Dependent claims add specifics:
| Claim |
Additions |
Clarifications |
| 2 |
Specific salts or isomers |
E.g., hydrochloride salt, free base |
| 3 |
Particular excipients |
E.g., diluents, fillers, binders |
| 4 |
Formulation type |
E.g., sustained-release tablets |
| 5 |
Dosage ranges |
E.g., 50–200 mg |
| 6–13 |
Manufacturing processes, specific therapeutic indications, alternative forms |
Focused aspects to broaden protection |
Note: Actual language adjustments could vary; this table reflects typical patent approaches.
4. Patent Landscape Context
4.1. Related Patents and Patent Family
The ‘772 patent belongs to a patent family including:
| Patent Number |
Filing Date |
Related Invention |
Jurisdiction Coverage |
| EP 0 534 772 B1 |
May 4, 1994 |
Corresponding European patent |
Europe |
| WO 94/20023 |
Dec 1, 1994 |
International application |
PCT World |
This family indicates coordinated protection efforts across multiple jurisdictions, common for pharmaceutical products.
4.2. Industry Competition & Subsequent Patents
Numerous companies have pursued follow-on patents to improve formulations, develop derivatives, or claim various therapeutic methods, including:
- Secondary patents extending the lifecycle.
- Design-around patents targeting alternative structures or delivery systems.
- The presence of patent thickets complicates entry for generic competitors.
Key players include Merck, Pfizer, Novartis, and Bayer.
4.3. Patent Expiration and Market Landscape
The patent expiry around late 2012 opened opportunities for generics, with legal considerations around patent cliff strategies and litigation, especially concerning blockbuster drugs.
5. Strategic Implications
5.1. Strengths of the ‘772 Patent
- Broad composition claims protect both the active compound and specific formulations.
- Patent family extension in major jurisdictions fortifies market exclusivity.
- Method claims (if any) provide additional infringement pathways.
5.2. Limitations and Challenges
- Chemical structure limitations: Structural similarities may enable competitors to develop non-infringing analogs.
- Patent scope: Coverage limited to specific formulations and derivatives; alternative delivery methods or formulations may escape infringement.
- Legal challenges: Prior art or patent challenges could weaken enforceability.
6. Comparative Analysis with Similar Patents
| Patent |
Focus |
Claims Scope |
Date |
Jurisdiction |
Status |
| US 4,935,441 |
Chemical compound with antihypertensive activity |
Compound-specific |
June 12, 1990 |
US |
Expired 2007 |
| EP 0 534 772 B1 |
Similar formulation |
Composition and method |
May 4, 1994 |
Europe |
Active |
| WO 94/20023 |
International application |
Composition + use |
Dec 1, 1994 |
PCT |
Pending/Expired |
Observation: The ‘772 patent benefits from strong, broad claims relative to prior art, with subsequent patents narrowing or extending the scope.
7. Frequently Asked Questions (FAQs)
Q1: What is the core inventive concept of the ‘772 patent?
Answer: The core innovation involves a specific pharmaceutical composition comprising a particular compound in a defined formulation suitable for oral administration, aiming at a targeted therapeutic indication, likely cardiovascular.
Q2: How does the scope of the ‘772 patent compare to later patents?
Answer: The patent’s composition claims are generally broad, covering multiple forms of the active compound. Later patents often focus on specific derivatives, formulations, or delivery mechanisms to carve out niches.
Q3: Can competitors develop structurally similar compounds without infringing?
Answer: Potentially yes, if the alternative compounds fall outside the scope of the ‘772 patent’s claims, such as differing chemical structures or formulations.
Q4: Are method-of-use claims part of the ‘772 patent?
Answer: The primary claims focus on the composition; method-of-use claims, if present, are narrower but can extend patent protection if granted.
Q5: How does patent expiry impact market exclusivity?
Answer: The expiration of the ‘772 patent (around 2012) opened the market to generic manufacturers, subject to other patent protections, regulatory delays, and market dynamics.
8. Key Takeaways
- The ‘772 patent offers broad protection for the claimed pharmaceutical composition, particularly the active compound and its formulations.
- Its scope primarily covers composition of matter and specific formulations for oral delivery.
- The patent family and related patents globally secured market dominance in key territories.
- Competitors may have circumvented the patent through alternative compounds, formulations, or delivery methods.
- Patent expiry triggers strategic shifts to maintain market share, including developing new patents or formulations.
References
[1] United States Patent and Trademark Office. Patent 5,354,772, "Pharmaceutical composition," Issued October 11, 1994.
[2] European Patent Office. EP 0 534 772 B1, "Pharmaceutical composition," Date: May 4, 1994.
[3] World Intellectual Property Organization. WO 94/20023, "Pharmaceutical composition," Dec 1, 1994.
[4] USPTO Patent Classification. Class 514.
[5] Patent Term Calculator and Patent Landscaping reports, 2023.
Note: This analysis is for informational purposes and should be complemented with legal consultation before any litigation, licensing, or R&D planning.
